Patent · US Expired

Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers

US6413513B1 · kind B1 · utility

11Cited by
0References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 6, 1999
Grant dateJul 2, 2002
Priority date
Expiry dateOct 6, 2019

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/4853
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.